Progenics Pharma (PGNX) Misses Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Progenics Pharma (PGNX) Misses Q3 EPS by 3c
November 7, 2016 7:55 AM EST
Received $50 Million Milestone Payment from Valeant Related to U.S. Approval of RELISTOR® TabletsCommercial Launch of RELISTOR® Tablets in September 2016On November 4th, Monetized Portion of RELISTOR Royalty Stream through $50 Million TransactionThird Quarter 2016 RELISTOR (SC and Oral) Net Sales of $22.1 MillionUltra-Orphan Radiotherapeutic Candidate AZEDRA® Registrational Trial Topline Results Expected First Quarter 2017Advancing Phase 3 Trial for 1404 Toward Interim Analysis by End of This YearOn Track to Initiate Phase 2/3 Trial of PyL Imaging Agent and Phase 1 Trial of 1095 This Year
NEW YORK, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc.... More
November 7, 2016 7:45 AM EST
NEW YORK, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced that its wholly-owned subsidiary MNTX Royalties Sub LLC has entered into a $50 million term loan agreement with a fund managed by HealthCare Royalty Partners (HCR) secured by, and to be repaid from, royalties from future sales of RELISTOR®.  Under the terms of the loan agreement, the lenders have no recourse to Progenics Pharmaceuticals, Inc., the parent company or to any of its assets other than the RELISTOR... More
